selected scholarly activity
-
conferences
- DETERMINANTS OF VIROLOGIC RELAPSE FOLLOWING HEPATITIS C ANTIVIRAL THERAPY: ANALYSIS OF THE CANADIAN POWER PROGRAM. Hepatology. 688A-688A. 2009
- OUTCOMES OF A LARGE, INCLUSIVE POPULATION-BASED HEPATITIS C TREATMENT PROGRAM ARE SIMILAR TO RANDOMIZED CONTROLLED TRIALS: INTERIM RESULTS OF THE CANADIAN REDIPEN PROGRAM. Hepatology. 703A-704A. 2009
- Consistency of sustained virologic response (SVR) across weight categories: Results from the Canadian power (peginterferon alfa-2B prospective optimal weight-based dosing response) program. Hepatology. 373A-374A. 2007
- An interim analysis of the Canadian power program (PEGinterferon alfa-2b prospective optimal weight-based dosing response): Consistent SVR rates across all weight categories. Hepatology. 324A-324A. 2006
- Exposure to ribavirin (RBV) predicts EVR and SVR in patients with HCV genotype 1 infection: Analysis of the Canadian pegasys expanded access program (EAP). Hepatology. 335A-336A. 2006
- 593 Treating chronic hepatitis C with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin in routine clinical practice: Factors predicting SVR using multiple logistic regression analysis. Journal of Hepatology. S220-S220. 2006
-
journal articles
- Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. European Journal of Clinical Microbiology and Infectious Diseases. 35:597-609. 2016
- Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada). Canadian Journal of Gastroenterology and Hepatology. 25:503-510. 2011
- Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy. Canadian Journal of Gastroenterology and Hepatology. 23:180-184. 2009
- Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin. Alimentary Pharmacology and Therapeutics. 28:43-50. 2008
- The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada. Canadian Journal of Gastroenterology and Hepatology. 22:388-392. 2008
- Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C. American Journal of Gastroenterology. 102:2181-2188. 2007
- Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon. Canadian Journal of Gastroenterology and Hepatology. 14:77B-81B. 2000
- Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. Journal of Hepatology. 16:249-250. 1992
- Altered Cyclosporine Absorption in a Patient with Ulcerative Colitis, Sclerosing Cholangitis and Pancreatic Insufficiency. Canadian Journal of Gastroenterology and Hepatology. 5:133-136. 1991
- The demography of primary biliary cirrhosis in ontario, canada. Hepatology. 12:98-105. 1990